NCT07590648Toborzás még nem indult4. fázis
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
Phase IV, Randomized, Open Label, Parallel Groups Clinical Trial for Evaluating the Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Oncohaematological Paediatric Patients (e-STOP 2)
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. máj. 15.
Rövid összefoglaló (regiszter, angolul)
The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker levels 48-72 hours after the episode. The main questions it aims to answer are: Is early discontinuation of antibiotics as safe as the standard strategy in terms of preventing invasive bacterial infections (such as sepsis, microbiologically documented infection, ICU admission, or death)? Does this strategy reduce the number of days on antibiotics without increasing infection-related complications? Researchers will compare early antibiotic discontinuation with the standard care strategy to see whether the early-stop approach provides similar safety while reducing antibiotic exposure. Participants will: Receive standard initial antibiotic therapy for febrile neutropenia. Undergo clinical and biomarker evaluations (including CRP and PCT). Be randomly assigned to: Experimental group: early discontinuation of antibiotics, or Control group: continuation of the standard antibiotic strategy. Be followed for 28 days after randomisation to monitor safety outcomes and treatment effects.
- Állapot (regiszter)
- Toborzás még nem indult
- Fázis (regiszter)
- 4. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 136 (tervezett)
- Első benyújtás
- 2026. febr. 16.
- Kezdés
- 2026. jún. 1.
- Elsődleges befejezés
- 2028. júl. 1.
- Fő szponzor
- Hospital Universitari Vall d'Hebron Research Institute
- Betegségek
- Gyermekkori daganatok
- NCT-szám
- NCT07590648
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 4. fázis
- Tervezett résztvevők: 136
- 2026. jún. 1. és az elsődleges befejezés (2028. júl. 1.) között
- 4 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Any condition which, in the investigator's opinion, makes study participation unsuitable for the patient or could limit, prevent, or confound the assessments planned in the protocol.
Egyéb
- Antibiotic treatment at the time of the FN episode different from that used prophylactically.
- Empirical antibiotic treatment different from that recommended in international guidelines.
- Patient with poor clinical evolution during the first 12 hours (hemodynamic instability, PICU admission, death).
- Active participation in the same study at the onset of the current FN episode.
- Active participation in another clinical trial that, in the investigators' opinion, may interfere with the assessment of the results.
- Female patients who are pregnant or breastfeeding
Kiket keres a vizsgálat
- Male and female patients ≤18 years of age expected to develop prolonged neutropenia (>7 days), with:
- Acute myeloblastic leukaemia at any phase of chemotherapy
- Acute lymphoblastic leukaemia in induction, consolidation, or intensification phases
- Biphenotypic leukaemia at any phase of chemotherapy
- Lymphoblastic lymphoma in induction and consolidation phases
- B-cell and anaplastic lymphoma receiving high-intensity chemotherapy
- Solid tumours receiving high-intensity chemotherapy
- Relapsed leukaemia at any phase of treatment
- Episode of febrile neutropenia (FN), defined as a single axillary temperature ≥38.0°C in a patient with an absolute neutrophil count (ANC) <500 neutrophils/mm³, or expected to fall below this value within the next 48-72 hours.
- Antibiotic treatment initiated for the current FN episode (routine antimicrobial prophylaxis is allowed, as well as teicoplanin 3 days/week for patients with AML included in the CHIP-AML-2022 protocol and therefore in the Pro-teico study).
- Low risk of invasive bacterial infection (IBI) at the start of the FN episode. Patients must meet all of the following:
- CRP <9 mg/dL
- PCT <0.5 ng/mL
- Absence of hypotension
- No microbiologically documented bacterial infection 48-72 hours after the FN episode.
- Good clinical evolution 48-72 hours after the FN episode, defined as:
- Afebrile for >48 hours (axillary temperature <38°C)
- Haemodynamically stable
- Stable paediatric early warning score (PEWS)
- CRP <5 mg/dL, or CRP <9 mg/dL and PCT <0.5 ng/mL, with decreasing trend at the time of randomisation (values will be assessed on day 3 and day 5 after the FN episode).
- ANC <500 neutrophils/mm³ at the time of randomisation.
- Signed informed consent from the patient and/or parent(s)/legal representative(s).
- Patient and/or parent(s)/legal representative(s) must have sufficient reading and writing skills to understand and provide consent to participate in the study.
- Patient and/or parent(s)/legal representative(s) must be considered reliable and capable of adhering to the protocol.
Életkor a regiszterben: - – 18 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (4)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spanyolország | Ismeretlen állapot |
| Hospital Sant Joan De Deu | Esplugues de Llobregat | Spanyolország | Ismeretlen állapot |
| Hospital Universitario La Paz | Madrid | Spanyolország | Ismeretlen állapot |
| Hospital Infantil Universitario Nino Jesus | Madrid | Spanyolország | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.